Evidence map›Paper›PMID 38705932›Full record

Observational studyPharmaceutical medicine2024

Trends in Adverse Event Reporting Before and After the Introduction of the Med Safety App in Nigeria.

Uchenna Geraldine Elemuwa, Fraden Bitrus, Ibrahim Adekunle Oreagba, Adeline Ijeoma Osakwe, Abiola Sadikat Abiodun, Kenneth Onu, Asmau Abubakar, Angela E Faniyi, Victoria Etuk, Daniel Yuah and 2 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Pharmaceutical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Uchenna Geraldine ElemuwaNational Agency for Food and Drug Administration and Control, Plot 2032, Olusegun Obasanjo Way, Abuja, Nigeria.
Fraden BitrusNational Agency for Food and Drug Administration and Control, Plot 2032, Olusegun Obasanjo Way, Abuja, Nigeria.
Ibrahim Adekunle OreagbaNational Drug Safety Advisory Committee, National Agency for Food and Drug Administration and Control, Abuja, Nigeria.ORCID 0000-0001-5360-448X
Adeline Ijeoma OsakweNational Drug Safety Advisory Committee, National Agency for Food and Drug Administration and Control, Abuja, Nigeria.
Abiola Sadikat AbiodunNational Agency for Food and Drug Administration and Control, Plot 2032, Olusegun Obasanjo Way, Abuja, Nigeria.
Kenneth OnuNational Agency for Food and Drug Administration and Control, Plot 2032, Olusegun Obasanjo Way, Abuja, Nigeria.
Asmau AbubakarNational Agency for Food and Drug Administration and Control, Plot 2032, Olusegun Obasanjo Way, Abuja, Nigeria.
Angela E FaniyiNational Agency for Food and Drug Administration and Control, Plot 2032, Olusegun Obasanjo Way, Abuja, Nigeria.
Victoria EtukInstitute of Human Virology Nigeria, Abuja, Nigeria.
Daniel YuahNational Agency for Food and Drug Administration and Control, Plot 2032, Olusegun Obasanjo Way, Abuja, Nigeria.
Rametu MomoduNational Agency for Food and Drug Administration and Control, Plot 2032, Olusegun Obasanjo Way, Abuja, Nigeria.
Christiana Mojisola AdeyeyeNational Agency for Food and Drug Administration and Control, Plot 2032, Olusegun Obasanjo Way, Abuja, Nigeria. cm.adeyeye@nafdac.gov.ng.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSpontaneous reporting of adverse events (AEs) is a mainstay of pharmacovigilance, and an ongoing challenge is how to ensure that more high-quality reports are collected for comprehensive information provision. The Med Safety App, a smartphone-based application, was launched in Nigeria in November 2020 to provide an electronic platform for users to seamlessly report AEs. There has been a paucity of evidence on the use of this application or other mobile applications for reporting adverse drug reactions/AEs following immunization in the Nigerian environment.

objectiveThe aim of this study was to evaluate the trends in adverse event reporting before and after the introduction of the Med Safety App in Nigeria.

methodsThis was a retrospective, observational study using data from the VigiFlow database to compare adverse event reporting in Nigeria before and after the deployment of the Med Safety App. The baseline period was 1st April 2019 to 30th October 2020 and the comparison period was 1st November 2020 to 31st May 2022. We used Vigilance Hub, the back-end system for the Med Safety App, to extract data on App downloads and de-identified user statistics. Data were summarized using descriptive statistics, frequencies and proportions. Quality was assessed by assigning a completeness score to each individual case safety report. The Kruskal-Wallis test was used to test for differences in medians between groups.

resultsFollowing deployment of the App, the Nigerian National Pharmacovigilance Centre recorded an increase in the total number of adverse event reports received in VigiFlow, from 2051 in the baseline period to 18,995 following deployment of the App, with 81.7% of those reported via the Med Safety App. There was a reduction in the proportion of paper-based reporting from 98.4 to 15.7% post-deployment, and direct reporting by consumers increased from 2.7 to 17.6%. Of the 15,526 reports submitted via the App, 15,111 (97.3%) had a completeness score above 70% and 6993 (45%) had a completeness score of 100%. The median completeness score of adverse event reports on the Med Safety App was 6 out of 7. On bivariate analysis using the Kruskal-Wallis test, there was an association between means of reporting and completeness score, and this association was significant, with a p value of 0.0001, which may reflect the validation rules that are applied within the App.

conclusionDeployment of the Med Safety App increased both the number and quality of adverse event reports; however, more awareness and capacity building are needed to strengthen and sustain reporting on the tool by all categories of healthcare professionals and consumers/patients.

Indexed as

Adverse Drug Reaction Reporting SystemsDrug-Related Side Effects and Adverse ReactionsMobile ApplicationsPharmacovigilanceDatabases, FactualHumansNigeriaRetrospective StudiesSmartphone

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.